
Merck is to improve its pipeline of hepatitis C virus (HCV) treatments by splashing out $3.85 billion on biopharma firm …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

